Home
Valuation

Work Area: Valuation

WiLAN revenues plummet in Q3 on prior year but Micron deal excluded

Strategic review of the licensing business nears a year in motion with no news on potential divestment announced

Drug royalty agreements can help Big Pharma overcome patent cliffs, says top dealmaker

Behzad Khosrowshahi, CEO of DRI Healthcare Trust, looks at recent deals the firm has done, explains what makes a transaction attractive and how to get one over the line

IP finance, monetisation and much more take centre stage on Day One of IPBC Asia 2022

A broad range of subjects and talking points - including a plenary address from JPO Commissioner Koichi Hamano - kept the 400+ delegates engaged as the event got underway in Tokyo

Latest content

IP analytics unicorn emerges with Softbank, Tencent backing

Singapore-based PatSnap says its latest round of fundraising pushed its valuation north of $1 billion

19 March 2021

Japanese government to weigh SEP licensing questions again

New group includes big names from the corporate IP world, representing Japanese stakeholders from both the auto and the electronics industries

17 March 2021

What life sciences businesses need to know about data commercialisation

A strategy for protecting and exploiting data is now a must for entities involved in healthcare research

25 February 2021

Seven top IP tips for biotech SMEs

How smaller biotechs can best overcome pitfalls and maximise the value of their inventions

18 February 2021

How an army of armchair investors showed why BlackBerry is seeking buyers for its 38,000 patents

The Canadian tech giant has built a licensing operation that brings in more than $300 million annually, but those gains have failed to shift shareholder sentiment

17 February 2021